News & Resources | NAYA Therapeutics

top of page

Screenshot 2025-03-31 at 14.38.32.png

NAYA Therapeutics Corporate Presentation

February 2026

NAYA Therapeutics Appoints Jason D. Hurt, MD, MBA as Chief Medical Officer

February 17th, 2026

NAYA Therapeutics Announces European Research & Manufacturing Hub At Paris-Saclay Cancer Cluster

January 7th, 2026

NAYA to Present at Network for Optimized Astatine-Labeled Radiopharmaceuticals (NOAR) Europe Annual Meeting

November 4th, 2025

NAYA Announces Partnership with Alpha Nuclide to Support Clinical Development in China for Its GPC3-Targeting Astatine-211 Alpha Therapy for HCC

October 13th, 2025

Astatine-211 Webinar Highlights
September 2nd, 2025

NAYA to Partner With Atley Solutions To Accelerate The Development of Its Astatine-211 Radiopharmaceuticals
September 2nd, 2025

Bio2Bedside Interview Featuring NAYA CEO Dr. Daniel Teper & Scientific Advisor Professor Yaron Ilan

August 28th, 2025

Astatine-211 Webinar (Hosted by NAYA Therapeutics)

August 27th, 2025

NAYA Therapeutics Partners With IONETIX to Build a US Production & Supply Network for Astatine-211 Targeted Alpha Therapies

August 21st, 2025

H.C. Wainwright Immune Cell Engager Virtual Conference Presentation

June 24th, 2025

NAYA Expands its HCC Pipeline With First-in-Class GPC3-Targeted Astatine-211 Alpha Radioimmunotherapy

June 17th, 2025

Multispecific Trial Supply Stability Hinges On CDMO Agility (BioProcess Online)

June 10th, 2025

NAYA Enters into Definitive Agreements to Regain Full Rights to Next-Gen Cancer Immunotherapies As It Advances Towards Clinical Milestones

Scrip M&A Podcast (with NAYA CEO Daniel Teper)

bottom of page